Coherus And Junshi Biosciences Announce Publication Of Final Overall Survival Results Of JUPITER-02, A Phase 3 Trial Evaluating LOQTORZI As Treatment For Nasopharyngeal Carcinoma, In The Journal Of The American Medical Association
Portfolio Pulse from Benzinga Newsdesk
Coherus BioSciences, Inc. (NASDAQ: CHRS) and Shanghai Junshi Biosciences announced the publication of final overall survival results from the JUPITER-02 Phase 3 trial of LOQTORZI for nasopharyngeal carcinoma (NPC) in JAMA. The study showed a 37% reduction in the risk of death when LOQTORZI is combined with chemotherapy compared to chemotherapy alone. LOQTORZI is the first FDA-approved treatment for NPC and is set to be available in the U.S. in January 2024. The treatment is expected to become the new standard of care for NPC.
November 28, 2023 | 4:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Coherus BioSciences' LOQTORZI, an anti-PD-1 monoclonal antibody, demonstrated significant survival benefits in a Phase 3 trial for NPC and is approved by the FDA. It is expected to launch in the U.S. in January 2024, potentially becoming a new standard of care for NPC.
The positive final overall survival results from the JUPITER-02 trial and the FDA approval of LOQTORZI position Coherus BioSciences favorably for potential revenue growth once the treatment is launched. As the first FDA-approved treatment for NPC, LOQTORZI could capture a significant market share, likely leading to increased investor interest and a positive short-term impact on CHRS stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100